Literature DB >> 8221693

Production of transgenic mice expressing the Ki-ras oncogene under the control of a thyroglobulin promoter.

G Santelli1, V de Franciscis, G Portella, G Chiappetta, A D'Alessio, D Califano, R Rosati, A Mineo, C Monaco, G Manzo.   

Abstract

Transgenic mice have been generated bearing three fusion genes consisting of: (a) a 900-base pair rat thyroglobulin promoter followed by a gene coding for a chloramphenicol acetyl transferase activity; (b) the same promoter followed by the complementary DNA of the human activated Ki-ras oncogene; (c) a 2000-base pair rat thyroglobulin promoter followed by the complementary DNA of the human activated Ki-ras. We have shown that the 900-base pair rat thyroglobulin promoter is able to direct the expression of the reporter gene specifically in the thyroid gland of transgenic mice. The mice bearing the two Ki-ras constructs, which express the transgene in thyroid glands, show thyroid abnormalities, although at very low incidence. These lesions appear after a long latency and with a benign aspect, thus suggest that, in agreement with literature data on naturally occurring human thyroid tumors, the action of an activated ras gene is not sufficient to attain a complete malignant conversion of thyroid glands in vivo. However, ras expression in thyroid follicular cells represents a favorable ground for tumor development, as shown by the fact that goitrogen stimulation experiments increase the occurrence of tumors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221693

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.

Authors:  K M La Perle; S M Jhiang; C C Capen
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 2.  Oncogenes and anti-oncogenes in human epithelial thyroid tumors.

Authors:  S Said; M Schlumberger; H G Suarez
Journal:  J Endocrinol Invest       Date:  1994-05       Impact factor: 4.256

3.  An Update on the Biology of RAS/RAF Mutations in Colorectal Cancer.

Authors:  Mandayam O Nandan; Vincent W Yang
Journal:  Curr Colorectal Cancer Rep       Date:  2011-06-01

Review 4.  Mouse models of thyroid cancer: A 2015 update.

Authors:  Lawrence S Kirschner; Zahida Qamri; Suresh Kari; Amruta Ashtekar
Journal:  Mol Cell Endocrinol       Date:  2015-06-27       Impact factor: 4.102

Review 5.  Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

6.  Modeling follicular thyroid cancer for future therapies.

Authors:  Xuguang Zhu; Sheue-Yann Cheng
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

Review 7.  Lessons from mouse models of thyroid cancer.

Authors:  Caroline S Kim; Xuguang Zhu
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

Review 8.  Modeling thyroid cancer in the mouse.

Authors:  X-G Zhu; S-Y Cheng
Journal:  Horm Metab Res       Date:  2009-04-08       Impact factor: 2.936

9.  Oncogenic potential of guanine nucleotide stimulatory factor alpha subunit in thyroid glands of transgenic mice.

Authors:  F M Michiels; B Caillou; M Talbot; F Dessarps-Freichey; M T Maunoury; M Schlumberger; L Mercken; R Monier; J Feunteun
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

10.  KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.

Authors:  Minjing Zou; Essa Y Baitei; Roua A Al-Rijjal; Ranjit S Parhar; Futwan A Al-Mohanna; Shioko Kimura; Catrin Pritchard; Huda BinEssa; Azizah A Alanazi; Ali S Alzahrani; Mohammed Akhtar; Abdullah M Assiri; Brian F Meyer; Yufei Shi
Journal:  Lab Invest       Date:  2015-07-06       Impact factor: 5.662

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.